Sveger T, Ohlsson K, Piitulainen E
Department of Paediatrics, University of Lund, University Hospital, Malmö, Sweden.
Pediatr Res. 1998 Dec;44(6):939-41. doi: 10.1203/00006450-199812000-00019.
Eighteen-year-old adolescents with alpha1-antitrypsin (alpha1AT) deficiency have mostly normal lung function tests. We hypothesized that compensatory increases in other protease inhibitors and/or a decreased leukocyte activity might favorably affect the protease/protease-inhibitor balance in alpha1AT-deficient adolescents. At the age of 18 y 46 PiZZ (severe deficiency), 22 PiSZ (moderate deficiency), and 41 control subjects were studied. The plasma protease inhibitors alpha2-macroglobulin (alpha2M), alpha1-antichymotrypsin (Achy), and secretory leukocyte protease inhibitor (SLPI) were studied, and the protease elastase complexed with alpha1AT (HEAT) and neutrophil gelatinase-associated lipocalin (NGAL) as indicators of neutrophil leukocyte activity. Significantly higher concentrations of alpha2M were found in PiZ (p < 0.0001) and PiSZ (p < 0.0001) individuals compared with control subjects. The PiZZ and SZ adolescents had low levels of NGAL (p < 0.0001). Low levels of HEAT were found in PiZZ subjects (p < 0.0005). Higher concentrations of Achy were found in PiZZ (p < 0.04) and PiSZ (p < 0.05) individuals. Increased concentrations of alpha2M and Achy combined with decreased levels of HEAT and NGAL, indicating decreased leukocyte activity may, to some extent, compensate for the protease/protease inhibitor imbalance in the alpha1AT-deficiency state.
患有α1抗胰蛋白酶(α1AT)缺乏症的18岁青少年的肺功能测试大多正常。我们推测,其他蛋白酶抑制剂的代偿性增加和/或白细胞活性的降低可能会对α1AT缺乏症青少年的蛋白酶/蛋白酶抑制剂平衡产生有利影响。在18岁时,对46名PiZZ型(严重缺乏)、22名PiSZ型(中度缺乏)和41名对照受试者进行了研究。研究了血浆蛋白酶抑制剂α2巨球蛋白(α2M)、α1抗糜蛋白酶(Achy)和分泌型白细胞蛋白酶抑制剂(SLPI),并将与α1AT复合的蛋白酶弹性蛋白酶(HEAT)和中性粒细胞明胶酶相关脂质运载蛋白(NGAL)作为中性粒细胞活性的指标。与对照受试者相比,PiZ型(p < 0.0001)和PiSZ型(p < 0.0001)个体的α2M浓度显著更高。PiZZ型和SZ型青少年的NGAL水平较低(p < 0.0001)。在PiZZ型受试者中发现HEAT水平较低(p < 0.0005)。在PiZZ型(p < 0.04)和PiSZ型(p < 0.05)个体中发现Achy浓度较高。α2M和Achy浓度的增加与HEAT和NGAL水平的降低相结合,表明白细胞活性降低可能在一定程度上补偿α1AT缺乏状态下的蛋白酶/蛋白酶抑制剂失衡。